Publications by authors named "Nicholas R Liguori"
Pancreatic cancer is a devastating disease with a poor prognosis. Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments. Lurbinectedin (PM01183; LY-01017) received FDA approval in 2020 for metastatic small cell lung cancer on or after platinum-based chemotherapy and is currently undergoing clinical trials in a variety of tumor types.
View Article and Find Full Text PDFArticle Synopsis
- Small cell lung cancer (SCLC) is a serious type of lung cancer that is really tough to treat, with a low survival rate of under 7%.
- A new combination of two drugs, ONC201 and lurbinectedin, has shown promise in effectively killing SCLC cells in tests.
- The combination therapy worked especially well for one specific cell line and caused less harm to healthy lung cells, making it a potential new treatment option.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by early metastasis, late detection, and poor prognosis. Progress towards effective therapy has been slow despite significant efforts. Novel treatment approaches are desperately needed and autophagy, an evolutionary conserved process through which proteins and organelles are recycled for use as alternative energy sources, may represent one such target.
View Article and Find Full Text PDFArticle Synopsis
- * Resistance to first-line therapies is a common challenge in SCLC, and despite some neuroendocrine features and mutations, the absence of actionable biomarkers complicates the development of more effective treatments.
- * New developments in treatment, like immune checkpoint inhibitors and agents like lurbinectedin and ONC201, show promise in clinical testing, with ONC201 activating stress responses and enhancing anti-tumor activity, currently being researched in combination for potential clinical trials.